CN110730661B - Ask1抑制剂化合物及其用途 - Google Patents
Ask1抑制剂化合物及其用途 Download PDFInfo
- Publication number
- CN110730661B CN110730661B CN201880037304.1A CN201880037304A CN110730661B CN 110730661 B CN110730661 B CN 110730661B CN 201880037304 A CN201880037304 A CN 201880037304A CN 110730661 B CN110730661 B CN 110730661B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- mmol
- cycloalkyl
- heteroaryl
- heterocycle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762482085P | 2017-04-05 | 2017-04-05 | |
| US62/482,085 | 2017-04-05 | ||
| PCT/US2018/026134 WO2018187506A1 (en) | 2017-04-05 | 2018-04-04 | Ask1 inhibitor compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110730661A CN110730661A (zh) | 2020-01-24 |
| CN110730661B true CN110730661B (zh) | 2023-06-13 |
Family
ID=63712299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880037304.1A Active CN110730661B (zh) | 2017-04-05 | 2018-04-04 | Ask1抑制剂化合物及其用途 |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US20210087167A1 (https=) |
| EP (1) | EP3606519B1 (https=) |
| JP (1) | JP7196093B2 (https=) |
| KR (1) | KR102665145B1 (https=) |
| CN (1) | CN110730661B (https=) |
| AR (1) | AR111407A1 (https=) |
| AU (1) | AU2018250217B2 (https=) |
| CA (1) | CA3059107A1 (https=) |
| CL (1) | CL2019002810A1 (https=) |
| CO (1) | CO2019011708A2 (https=) |
| CR (1) | CR20190503A (https=) |
| CU (1) | CU20190080A7 (https=) |
| DK (1) | DK3606519T3 (https=) |
| DO (1) | DOP2019000255A (https=) |
| EA (1) | EA201992299A1 (https=) |
| EC (1) | ECSP19078393A (https=) |
| ES (1) | ES2992084T3 (https=) |
| FI (1) | FI3606519T3 (https=) |
| HU (1) | HUE068103T2 (https=) |
| IL (1) | IL269711B (https=) |
| JO (1) | JOP20190221A1 (https=) |
| MA (1) | MA49047A (https=) |
| MX (1) | MX394098B (https=) |
| NI (1) | NI201900102A (https=) |
| NZ (1) | NZ758345A (https=) |
| PE (1) | PE20200009A1 (https=) |
| PH (1) | PH12019502288A1 (https=) |
| PL (1) | PL3606519T3 (https=) |
| PT (1) | PT3606519T (https=) |
| RU (1) | RU2019134679A (https=) |
| SG (1) | SG11201909155VA (https=) |
| SI (1) | SI3606519T1 (https=) |
| TW (1) | TWI779022B (https=) |
| WO (1) | WO2018187506A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6754505B2 (ja) * | 2017-01-22 | 2020-09-09 | 福建広生堂薬業股▲ふん▼有限公司 | Ａｓｋ１阻害剤、その調製方法および使用 |
| AU2018266911C1 (en) | 2017-05-12 | 2022-10-20 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| EP3735404B1 (en) | 2018-01-02 | 2023-11-29 | Seal Rock Therapeutics, Inc. | Ask1 inhibitor compounds and uses thereof |
| CN110407806B (zh) * | 2018-04-28 | 2021-08-17 | 深圳微芯生物科技股份有限公司 | 甲酰胺类化合物、其制备方法及其应用 |
| ES3004523T3 (en) | 2018-05-02 | 2025-03-12 | Enanta Pharm Inc | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2020006429A1 (en) * | 2018-06-28 | 2020-01-02 | Hepatikos Therapeutics, Llc | Ask1 isoindolin-1-one inhibitors and methods of use thereof |
| WO2020041417A1 (en) | 2018-08-22 | 2020-02-27 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2020106707A1 (en) | 2018-11-19 | 2020-05-28 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US11466033B2 (en) | 2019-03-25 | 2022-10-11 | Enanta Pharmaceuticals, Inc. | Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors |
| CN112409332B (zh) * | 2019-08-23 | 2023-12-08 | 广东东阳光药业股份有限公司 | 三氮唑衍生物及其在药物中的应用 |
| PE20221283A1 (es) | 2019-12-27 | 2022-09-05 | Lupin Ltd | Compuestos triciclicos sustituidos |
| PE20230323A1 (es) | 2020-05-01 | 2023-02-22 | Pfizer | Compuestos de azalactama como inhibidores de hpk1 |
| WO2021224818A1 (en) * | 2020-05-08 | 2021-11-11 | Pfizer Inc. | Isoindolone compounds as hpk1 inhibitors |
| JP7819176B2 (ja) * | 2020-08-03 | 2026-02-24 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| WO2024020458A1 (en) * | 2022-07-20 | 2024-01-25 | Seal Rock Therapeutics, Inc. | Method of treating organ diseases or disorders with ask1 inhibitors |
| TW202547513A (zh) | 2024-05-06 | 2025-12-16 | 法商Ｇｅｎｆｉｔ公司 | 敗血症的治療 |
| WO2026057806A1 (en) | 2024-09-13 | 2026-03-19 | Genfit | Injectable dosage form of 2-[6-(4-cyclopropyl-4h-1,2,4-triazol-3-yl)-2-pyridyl]-5-morpholinocarbonyl-1-isoindolinone |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102482257A (zh) * | 2009-07-13 | 2012-05-30 | 吉利德科学股份有限公司 | 凋亡信号调节激酶抑制剂 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| PL2531501T3 (pl) * | 2010-02-03 | 2014-05-30 | Takeda Pharmaceuticals Co | Inhibitory kinazy 1 regulującej sygnał apoptotyczny |
| WO2012079022A1 (en) * | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| ES2617339T3 (es) * | 2010-12-16 | 2017-06-16 | Calchan Limited | Derivados de pirrolopirimidina inhibidores de ASK1 |
| MX2017003933A (es) * | 2014-09-24 | 2017-06-30 | Gilead Sciences Inc | Metodos de tratamiento de la enfermedad hepatica. |
| US10669242B2 (en) | 2016-06-10 | 2020-06-02 | Venenum Biodesign, LLC | Clostridium difficile toxin inhibitors |
| WO2018133866A1 (zh) | 2017-01-22 | 2018-07-26 | 福建广生堂药业股份有限公司 | 作为ask1抑制剂的吡啶衍生物及其制备方法和应用 |
| JP6754505B2 (ja) * | 2017-01-22 | 2020-09-09 | 福建広生堂薬業股▲ふん▼有限公司 | Ａｓｋ１阻害剤、その調製方法および使用 |
| EP3580224B1 (en) | 2017-02-07 | 2022-07-13 | Biogen MA Inc. | Ask1 inhibiting agents |
| CN109071498B (zh) | 2017-02-16 | 2021-03-30 | 四川科伦博泰生物医药股份有限公司 | 激酶抑制剂及其制备方法和用途 |
| WO2018151830A1 (en) | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Pyridinyl based apoptosis signal-regulation kinase inhibitors |
| WO2018157277A1 (en) | 2017-02-28 | 2018-09-07 | Eli Lilly And Company | Isoquinolin and naphthydrin compounds |
| US11136324B2 (en) | 2017-03-03 | 2021-10-05 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Substituted imidazoles as apoptosis signal regulating kinase 1 inhibitors |
| JP2020512976A (ja) | 2017-03-27 | 2020-04-30 | ファーマケア，インク． | アポトーシスシグナル調節キナーゼ１（ａｓｋ１）阻害剤化合物 |
| EP3681499A4 (en) * | 2017-09-13 | 2021-04-21 | D.E. Shaw Research, LLC | CONNECTIONS AS RAS INHIBITORS AND THEIR USE |
| WO2020006429A1 (en) * | 2018-06-28 | 2020-01-02 | Hepatikos Therapeutics, Llc | Ask1 isoindolin-1-one inhibitors and methods of use thereof |
-
2017
- 2017-06-16 JO JOP/2019/0221A patent/JOP20190221A1/ar unknown
-
2018
- 2018-04-03 TW TW107111742A patent/TWI779022B/zh active
- 2018-04-04 US US16/499,075 patent/US20210087167A1/en not_active Abandoned
- 2018-04-04 CU CU2019000080A patent/CU20190080A7/es unknown
- 2018-04-04 CA CA3059107A patent/CA3059107A1/en active Pending
- 2018-04-04 PL PL18780760.7T patent/PL3606519T3/pl unknown
- 2018-04-04 ES ES18780760T patent/ES2992084T3/es active Active
- 2018-04-04 RU RU2019134679A patent/RU2019134679A/ru not_active Application Discontinuation
- 2018-04-04 PT PT187807607T patent/PT3606519T/pt unknown
- 2018-04-04 SI SI201831140T patent/SI3606519T1/sl unknown
- 2018-04-04 CR CR20190503A patent/CR20190503A/es unknown
- 2018-04-04 KR KR1020197032180A patent/KR102665145B1/ko active Active
- 2018-04-04 AU AU2018250217A patent/AU2018250217B2/en active Active
- 2018-04-04 EA EA201992299A patent/EA201992299A1/ru unknown
- 2018-04-04 SG SG11201909155V patent/SG11201909155VA/en unknown
- 2018-04-04 MA MA049047A patent/MA49047A/fr unknown
- 2018-04-04 MX MX2019012013A patent/MX394098B/es unknown
- 2018-04-04 FI FIEP18780760.7T patent/FI3606519T3/fi active
- 2018-04-04 JP JP2019553366A patent/JP7196093B2/ja active Active
- 2018-04-04 NZ NZ758345A patent/NZ758345A/en unknown
- 2018-04-04 CN CN201880037304.1A patent/CN110730661B/zh active Active
- 2018-04-04 WO PCT/US2018/026134 patent/WO2018187506A1/en not_active Ceased
- 2018-04-04 DK DK18780760.7T patent/DK3606519T3/da active
- 2018-04-04 HU HUE18780760A patent/HUE068103T2/hu unknown
- 2018-04-04 PE PE2019001990A patent/PE20200009A1/es unknown
- 2018-04-04 EP EP18780760.7A patent/EP3606519B1/en active Active
- 2018-04-05 AR ARP180100846A patent/AR111407A1/es active IP Right Grant
- 2018-05-03 US US15/970,587 patent/US10150755B2/en active Active
-
2019
- 2019-09-26 IL IL269711A patent/IL269711B/en unknown
- 2019-10-02 CL CL2019002810A patent/CL2019002810A1/es unknown
- 2019-10-03 PH PH12019502288A patent/PH12019502288A1/en unknown
- 2019-10-03 NI NI201900102A patent/NI201900102A/es unknown
- 2019-10-04 DO DO2019000255A patent/DOP2019000255A/es unknown
- 2019-10-23 CO CONC2019/0011708A patent/CO2019011708A2/es unknown
- 2019-10-31 EC ECSENADI201978393A patent/ECSP19078393A/es unknown
-
2024
- 2024-09-26 US US18/897,798 patent/US20250304552A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102482257A (zh) * | 2009-07-13 | 2012-05-30 | 吉利德科学股份有限公司 | 凋亡信号调节激酶抑制剂 |
Non-Patent Citations (5)
| Title |
|---|
| Conscious uncoupling in NASH;M. Teresa Villanueva 等;《Nature Reviews Drug Discovery》;20170330;第16卷;第239页 * |
| Copper-Catalyzed Intramolecular Benzylic C–H Amination for the Synthesis of Isoindolinones;Chiaki Yamamoto等;《J. Org. Chem.》;20160809;第1-32页 * |
| Efficient and Convenient Synthesis of Indazol-3(2H)-ones and 2-Aminobenzonitriles;Guolan Dou等;《 J.Comb.Chem》;20091231;第11卷;第1073-1077页 * |
| Lanier, Marion等.Structure/Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure.《ACS Medicinal Chemistry Letters》.2017,第8卷(第3期),第316-320页. * |
| Structure/Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure;Lanier, Marion等;《ACS Medicinal Chemistry Letters》;20170208;第8卷(第3期);第316-320页 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110730661B (zh) | Ask1抑制剂化合物及其用途 | |
| CN105828820B (zh) | 布罗莫结构域抑制剂 | |
| CN110049982A (zh) | 杂环fxr调节剂 | |
| CN105992759B (zh) | 1,2-萘醌的衍生物及其制备方法 | |
| WO2018059314A1 (zh) | 氮杂双环衍生物及其制备方法和用途 | |
| KR20110037883A (ko) | 잔틴 옥시다아제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물 | |
| CN103200820A (zh) | 作为s-亚硝基谷胱甘肽还原酶抑制剂的新颖的取代喹啉化合物 | |
| TWI718146B (zh) | 新穎的5-脂氧合酶啟動蛋白（ｆｌａｐ）抑制劑 | |
| WO2017157332A1 (zh) | 芳香酰胺类衍生物、其制备方法及其在医药上的应用 | |
| CN108863850B (zh) | 联芳基类化合物及其制备方法和用途 | |
| CN109937201A (zh) | 乙型肝炎核心蛋白调节剂 | |
| CN115413279A (zh) | P2x3调节剂 | |
| CN106068265A (zh) | 用于治疗代谢病症的二氢吡啶酮mgat2抑制剂 | |
| KR20220044330A (ko) | 수용체-상호작용 단백질-1 키나아제 저해제로서의 융합된 고리 헤테로아릴 화합물 | |
| CN103874697A (zh) | 二苯并氧杂*衍生物 | |
| CN111801314B (zh) | Ask1抑制剂化合物及其用途 | |
| CN111902401B (zh) | 受体抑制剂、包含其的药物组合物及其用途 | |
| HK40013582A (en) | Ask1 inhibitor compounds and uses thereof | |
| HK40013582B (en) | Ask1 inhibitor compounds and uses thereof | |
| WO2017173960A1 (zh) | 一类抑制丙肝病毒的大环状杂环化合物及其制备和用途 | |
| BR112019021021B1 (pt) | Compostos de inibidor de ask1, usos dos mesmos e composições farmacêuticas | |
| EA040632B1 (ru) | Соединения, ингибирующие ask1, и их применение | |
| WO2025067475A1 (zh) | 一类镇痛的化合物及其制备方法和用途 | |
| HK40049264B (zh) | 吡咯酰胺类化合物及其用途 | |
| WO2021136326A1 (zh) | 芳香酰胺类化合物及其在药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40013582 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |